These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23000236)

  • 1. Emergence of tigecycline-resistant Klebsiella pneumoniae after tigecycline therapy for complicated urinary tract infection caused by carbapenem-resistant Escherichia coli.
    Tsai HY; Liao CH; Cheng A; Liu CY; Huang YT; Sheng WH; Hsueh PR
    J Infect; 2012 Dec; 65(6):584-6. PubMed ID: 23000236
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence of tigecycline resistance amongst multi-drug resistant gram negative isolates in a multi-disciplinary hospital.
    Arya SC; Agarwal N
    J Infect; 2010 Oct; 61(4):358-9. PubMed ID: 20670647
    [No Abstract]   [Full Text] [Related]  

  • 3. Regional variations in multidrug resistance among Enterobacteriaceae in the USA and comparative activity of tigecycline, a new glycylcycline antimicrobial.
    DiPersio JR; Dowzicky MJ
    Int J Antimicrob Agents; 2007 May; 29(5):518-27. PubMed ID: 17376657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.
    Naesens R; Ursi JP; Van Schaeren J; Jeurissen A
    Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):381-4. PubMed ID: 18802728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.
    Livermore DM; Mushtaq S; Warner M; Woodford N
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3840-4. PubMed ID: 27044556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates.
    Fritsche TR; Strabala PA; Sader HS; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):209-13. PubMed ID: 16105566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline.
    Livermore DM; Warner M; Mushtaq S; Doumith M; Zhang J; Woodford N
    Int J Antimicrob Agents; 2011 May; 37(5):415-9. PubMed ID: 21429716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2015 Oct; 83(2):183-6. PubMed ID: 26164275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay.
    Pournaras S; Vrioni G; Neou E; Dendrinos J; Dimitroulia E; Poulou A; Tsakris A
    Int J Antimicrob Agents; 2011 Mar; 37(3):244-7. PubMed ID: 21236643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program.
    Wise MG; Estabrook MA; Sahm DF; Stone GG; Kazmierczak KM
    PLoS One; 2018; 13(4):e0195281. PubMed ID: 29608599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility of global intra-abdominal Enterobacteriaceae isolates to tigecycline (TEST 2007-2010).
    Hawser SP; Lob S; Hoban D; Bouchillon S; Badal R
    J Infect; 2012 Jun; 64(6):620-2. PubMed ID: 22326560
    [No Abstract]   [Full Text] [Related]  

  • 13. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
    Morosini MI; García-Castillo M; Coque TM; Valverde A; Novais A; Loza E; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2695-9. PubMed ID: 16870760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.
    Huang TD; Berhin C; Bogaerts P; Glupczynski Y
    J Antimicrob Chemother; 2012 Nov; 67(11):2696-9. PubMed ID: 22833638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria.
    Iredell J; Thomas L; Power D; Mendes E
    J Antimicrob Chemother; 2007 Apr; 59(4):816-8. PubMed ID: 17353224
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
    Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibilities of clinical isolates of carbapenemase-producing Enterobacteriaceae to fosfomycin and tigecycline.
    Choudhury S; Yeng JL; Krishnan PU
    Clin Microbiol Infect; 2015 Oct; 21(10):e75-6. PubMed ID: 26086572
    [No Abstract]   [Full Text] [Related]  

  • 19. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colistin-resistant Enterobacteriaceae infections: clinical and molecular characterization and analysis of in vitro synergy.
    de Maio Carrillho CM; Gaudereto JJ; Martins RC; de Castro Lima VA; de Oliveira LM; Urbano MR; Perozin JS; Levin AS; Costa SF
    Diagn Microbiol Infect Dis; 2017 Mar; 87(3):253-257. PubMed ID: 27939820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.